![Novo Nordisk's Ozempic approved in the US for CV risk reduction in people with type 2 diabetes and established CVD - Nordic Life Science – the leading Nordic life science news service Novo Nordisk's Ozempic approved in the US for CV risk reduction in people with type 2 diabetes and established CVD - Nordic Life Science – the leading Nordic life science news service](https://nordiclifescience.org/wp-content/public_html/2017/03/mads-krogsgaard-tomsen-1-900x675.jpg)
Novo Nordisk's Ozempic approved in the US for CV risk reduction in people with type 2 diabetes and established CVD - Nordic Life Science – the leading Nordic life science news service
![Novo Nordisk adapts Rybelsus launch to the coronavirus era - Campaigns - MM+M - Medical Marketing and Media Novo Nordisk adapts Rybelsus launch to the coronavirus era - Campaigns - MM+M - Medical Marketing and Media](https://www.mmm-online.com/wp-content/uploads/sites/2/2020/07/GettyImages-1171388860.jpg)
Novo Nordisk adapts Rybelsus launch to the coronavirus era - Campaigns - MM+M - Medical Marketing and Media
![Novo Nordisk: Rybelsus ICER Report Justifies Price, Januvia The Likely Victim (NYSE:NVO) | Seeking Alpha Novo Nordisk: Rybelsus ICER Report Justifies Price, Januvia The Likely Victim (NYSE:NVO) | Seeking Alpha](https://static.seekingalpha.com/uploads/2019/12/12/48772731-15762122840944304_origin.png)
Novo Nordisk: Rybelsus ICER Report Justifies Price, Januvia The Likely Victim (NYSE:NVO) | Seeking Alpha
![NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS” | by Bare Sky Marketing — Healthcare Content Writing | Medium NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS” | by Bare Sky Marketing — Healthcare Content Writing | Medium](https://miro.medium.com/max/614/1*qQudqyLwOskE4KV2GaIjng.jpeg)
NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS” | by Bare Sky Marketing — Healthcare Content Writing | Medium
![Novo Nordisk's Rybelsus (semaglutide) is a first oral GLP-1 treatment for type 2 diabetes mellitus - YouTube Novo Nordisk's Rybelsus (semaglutide) is a first oral GLP-1 treatment for type 2 diabetes mellitus - YouTube](https://i.ytimg.com/vi/FAgXOZ1pJow/mqdefault.jpg)